» Articles » PMID: 32874571

Neuroprotective Effects of the Aerial Parts of Willd Extract on Scopolamine-induced Learning and Memory Impairments in Mice

Overview
Journal Biomed Rep
Specialty Biochemistry
Date 2020 Sep 3
PMID 32874571
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is a common neurodegenerative disease characterized by progressive cognitive dysfunction and behavioral impairment. Aerial parts of Willd (APT) is a traditional Chinese medicine used for the treatment of amnesia. The present study aimed to investigate the protective effects of APT on scopolamine-induced learning and memory impairments in mice. Scopolamine-induced mice were used to determine the effects of APT on learning and memory impairment. Mice were orally administered with APT (25, 50 and 100 mg/kg) and piracetam (750 mg/kg) for 14 days, and intraperitoneally injected with scopolamine (2 mg/kg) from days 8 to 14. Morris water maze and step-down tests were performed to evaluate learning and memory. Levels of acetylcholine (ACh), choline acetyltransferase (ChAT), acetylcholinesterase (AChE), interleukin (IL)-1β, IL-10 and brain-derived neurotrophic factor (BDNF) in the hippocampus and frontal cortex were measured by ELISA. Superoxide dismutase (SOD), malondialdehyde (MDA) and glutathione (GSH) were measured via biochemical detection. The results demonstrated that APT ameliorated learning and memory impairment in scopolamine-induced mice. Correspondingly, APT significantly increased ACh and ChAT levels in the hippocampus and prefrontal cortex of scopolamine-induced mice. Additionally, treatment with APT significantly increased BDNF and IL-10 levels, and decreased IL-1β and AChE levels in the same mice. Furthermore, APT significantly increased SOD activity and GSH content, and decreased MDA levels in brain tissue. These results indicated that APT may ameliorate learning and memory impairment by regulating cholinergic activity, promoting BDNF and inhibiting neuroinflammation and oxidative stress.

Citing Articles

Development, Statistical Optimization, and Characterization of Resveratrol-Containing Solid Lipid Nanoparticles (SLNs) and Determination of the Efficacy in Reducing Neurodegenerative Symptoms Related to Alzheimer's Disease: In Vitro and In Vivo Study.

Khishvand M, Yeganeh E, Zarei M, Soleimani M, Mohammadi M, Mahjub R Biomed Res Int. 2024; 2024:7877265.

PMID: 39376256 PMC: 11458308. DOI: 10.1155/2024/7877265.


A review of the botany, metabolites, pharmacology, toxicity, industrial applications, and processing of Polygalae Radix: the "key medicine for nourishing life".

Kuang H, Kong L, Hou A, Yang A, Jiang H Front Pharmacol. 2024; 15:1450733.

PMID: 39359244 PMC: 11445616. DOI: 10.3389/fphar.2024.1450733.


Multi-target regulatory mechanism of Yang Xin Tang - a traditional Chinese medicine against dementia.

Lo T, Chan A, Cheung S, Yung L, Leung M, Wong Y Chin Med. 2023; 18(1):101.

PMID: 37587513 PMC: 10428601. DOI: 10.1186/s13020-023-00813-w.


Qualitative and quantitative analysis of the bioactive components of "ginseng-polygala" drug pair against PC12 cell injury based on UHPLC-QTOF-MS and HPLC.

Wang Z, Sun X, Zhao Y, Ga L, Li Q, Li Q Front Pharmacol. 2022; 13:949757.

PMID: 36569314 PMC: 9780267. DOI: 10.3389/fphar.2022.949757.


Chinese herbal medicine for mild cognitive impairment using mini-mental state examination: A systematic review and meta-analysis.

Wang W, Diwu Y, Liu Q, Zhou Y, Sayed T, Wang D Medicine (Baltimore). 2021; 100(38):e27034.

PMID: 34559097 PMC: 8462642. DOI: 10.1097/MD.0000000000027034.


References
1.
Pepeu G, Giovannini M . The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Res. 2017; 1670:173-184. DOI: 10.1016/j.brainres.2017.06.023. View

2.
Teipel S, Heinsen H, Amaro Jr E, Grinberg L, Krause B, Grothe M . Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging. 2013; 35(3):482-91. PMC: 4120959. DOI: 10.1016/j.neurobiolaging.2013.09.029. View

3.
Kinney J, Bemiller S, Murtishaw A, Leisgang A, Salazar A, Lamb B . Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4:575-590. PMC: 6214864. DOI: 10.1016/j.trci.2018.06.014. View

4.
Krivinko J, Koppel J, Savonenko A, Sweet R . Animal Models of Psychosis in Alzheimer Disease. Am J Geriatr Psychiatry. 2019; 28(1):1-19. PMC: 6858948. DOI: 10.1016/j.jagp.2019.05.009. View

5.
Morgan A, Touchard S, Leckey C, OHagan C, Nevado-Holgado A, Barkhof F . Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimers Dement. 2019; 15(6):776-787. PMC: 6565806. DOI: 10.1016/j.jalz.2019.03.007. View